Online inquiry

IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14319MR)

This product GTTS-WQ14319MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFL7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016215.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51162
UniProt ID Q9UHF1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14319MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4937MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ4007MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ10883MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ11104MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ14795MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ14881MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ12661MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ334MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 1F5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW